Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada.
D000328:Adult; D000368:Aged; D017311:Amlodipine / Q000008:administration & dosage / Q000191:economics*; D001713:Biphenyl Compounds / Q000008:administration & dosage / Q000191:economics*; D015331:Cohort Studies; D003362:Cost-Benefit Analysis; D003928:Diabetic Nephropathies / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics; D016527:Drug Costs; D005260:Female; D017048:Health Care Costs; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D000077405:Irbesartan; D008297:Male; D008390:Markov Chains; D008875:Middle Aged; D009864:Ontario; D012016:Reference Values; D012680:Sensitivity and Specificity; D013777:Tetrazoles / Q000008:administration & dosage / Q000191:economics*
D001713:Biphenyl Compounds; D013777:Tetrazoles; D017311:Amlodipine; D000077405:Irbesartan